Lifestyle-related Early Detection and Intervention for Older Adults & Elderly at Risk for Metabolic Syndrome

NCT ID: NCT05031299

Last Updated: 2021-09-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

960 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-03-01

Study Completion Date

2022-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In GATEKEEPER intervention, Big Data Analytics techniques will be exploited to address risk stratification and early detection, based on lifestyles analysis including: pattern recognition for the improvement of public health surveillance and for the early detection of chronic conditions; data mining for inductive reasoning and exploratory data analysis; Cluster Analysis for identifying high-risk groups among elder citizens. In the above cases timely intervention is provided by through AI-based, digital coaches, structured conversations, consultation and education. The main target group (N=960) is older adults and elderly citizens with risk factors for MetS and their carers. Therefore, the GATEKEEPER intervention aims at primary (avoid occurrence of disease) and secondary (early detection and management) prevention of the ageing population at risk for MetS.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Over 1.5 billion people worldwide are affected by Metabolic Syndrome (MetS) - a cluster of conditions reflecting behavioural risk factors typical of modern lifestyle (excessive food intake, low physical activity, etc) - with a huge socioeconomic impact and a total estimated cost of trillions of euros.

Early prevention measures especially for elderly at high risk of chronic conditions, such as prediabetics or obese, include structured lifestyle change programs that help people achieve and sustain changes in dietary and physical activity habits.

It is well established that MetS prevalence, as well as its individual components (high blood pressure, high glucose, central adiposity) increase with age. Notably, MetS percentages in the age group 50-55 years old and older is almost 2-3 times higher than in the younger age groups, probably due to a life time accumulation of adversities including overnutrition, a sedentary lifestyle, obesity and dyslipidemia, changes in the hormones, untreated hypertension, changes of the functioning of beta cells and other environmental and physiological factors.

Therefore, it is important to target not only elderly citizens, but rather older adults aged ≥55 years old as the optimum target group for a MetS prevention intervention.

In GATEKEEPER intervention, Big Data Analytics techniques will be exploited to address risk stratification and early detection, based on lifestyles analysis including: pattern recognition for the improvement of public health surveillance and for the early detection of chronic conditions; data mining for inductive reasoning and exploratory data analysis; Cluster Analysis for identifying high-risk groups among elder citizens. In the above cases timely intervention is provided by through AI-based, digital coaches, structured conversations, consultation and education. The main target group (N=960) is older adults and elderly citizens with risk factors for MetS and their carers. Therefore, the GATEKEEPER intervention aims at primary (avoid occurrence of disease) and secondary (early detection and management) prevention of the ageing population at risk for MetS.

960 older adults and elderly citizens (aged \>=55 years old) with risk factors for MetS as well as their carers (n=40) will be recruited and will be randomized to either: i) the intervention group 1 (n=320), who will be provided with the standard care plus a lifestyle application to promote self-management, increase health literacy and awareness through a digital coach, ii) the intervention group 2 (n=320), who will be provided with the standard care, the lifestyle application and additionally digital tools and wearables, such as a smart tracker and weight scale, or iii) the control group (n=320), who will only receive standard care, as provided by the local and national healthcare system as well as one face-to-face counselling session for lifestyle modification to improve their risk factors.

The participants will be followed up for a total duration of 3 months, when they will be re-evaluated to assess whether their risk factors were improved through the lifestyle intervention.

The users will be recruited at local community centres, such as the "Open Day Elderly Centres", health centres, private offices of health care professionals, hospitals etc. upon written informed consent form.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Metabolic Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

The present study is a cluster-randomized lifestyle intervention aimed at primary and secondary prevention of MetS, including three study arms: standard care (control group), standard care plus lifestyle application (intervention group 1) and standard care plus lifestyle application and wearables and devices (intervention group 2). It is conducted with older adults and elderly (aged ≥55 years old) living at home and at risk for MetS, as well as their carers. The total duration of the intervention for each participant will be 3 months.
Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control group (Standard care)

Participants in the control group will receive only the standard care as provided by the local and national healthcare system as well as one face-to-face counselling session for lifestyle modification to improve their risk factors for 3 months.

Group Type ACTIVE_COMPARATOR

Standard care

Intervention Type BEHAVIORAL

Participants will receive only the standard care as provided by the local and national healthcare system as well as one face-to-face counselling session for lifestyle modification to improve their risk factors.

Intervention group 1 (Application)

Participants will will be additionally provided with a health-promotion application for self-management for 3 months.

Group Type EXPERIMENTAL

Health-promotion application for self-management

Intervention Type BEHAVIORAL

Participants will be provided with a health-promotion application for self-management for 3 months, additionally to the standard care.

Intervention group 2 (Devices)

Participants will be additionally provided with wearables and devices for 3 months including:

* A weighing scale (assessing also body composition) device
* A smartwatch/wristband to assess physical activity but also sleep pattern.

Group Type EXPERIMENTAL

Wearables and devices

Intervention Type DEVICE

Participants will be provided with wearables and devices, including a weighing scale (assessing also body composition) device and a smartwatch/wristband to assess physical activity but also sleep pattern, for 3 months, additionally to the standard care and the Health-promotion application.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Standard care

Participants will receive only the standard care as provided by the local and national healthcare system as well as one face-to-face counselling session for lifestyle modification to improve their risk factors.

Intervention Type BEHAVIORAL

Health-promotion application for self-management

Participants will be provided with a health-promotion application for self-management for 3 months, additionally to the standard care.

Intervention Type BEHAVIORAL

Wearables and devices

Participants will be provided with wearables and devices, including a weighing scale (assessing also body composition) device and a smartwatch/wristband to assess physical activity but also sleep pattern, for 3 months, additionally to the standard care and the Health-promotion application.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Males and females aged ≥55 years old
* Having any of the following risk factors for MetS:

* waist circumference \>94 cm for men and \>80 cm for women
* Triglycerides (TG) ≥150 mg/dL
* High-density lipoprotein cholesterol (HDL-C) \<40 mg/dL for men and \<50 mg/dL for women
* Fasting glucose ≥100 mg/dL
* Blood pressure ≥130 /≥85 mm Hg
* Living at home (either alone or with relatives)
* Informed consent form provided

Exclusion Criteria

* Having severe hearing or vision problems or any other acute or chronic condition that would limit the ability of the user to participate in the study
* Having dementia or cognitive impairment
* Being institutionalised
* Participation in another research project
Minimum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

CitiesNet

UNKNOWN

Sponsor Role collaborator

University of Thessaly

OTHER

Sponsor Role collaborator

University of Patras

OTHER

Sponsor Role collaborator

BioAssist

UNKNOWN

Sponsor Role collaborator

University of Ioannina

OTHER

Sponsor Role collaborator

Centre for Research & Technology Hellas (CERTH)

UNKNOWN

Sponsor Role collaborator

Harokopio University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Yannis Manios

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Odysseas Androutsos, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Thessaly

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Harokopio University of Athens

Kallithea, Attica, Greece

Site Status RECRUITING

University of Thessaly

Trikala, , Greece

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Greece

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Yannis Manios, PhD

Role: CONTACT

+30 210 9549156

Eva Karaglani, PhD-c

Role: CONTACT

+30 210 9549340

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Yannis Manios, PhD

Role: primary

+30 2109549156

Eva Karaglani, PhD-c

Role: backup

+30 210 9549340

Odysseas Androutsos, PhD

Role: primary

+30 6944290774

Maria Vlahava, PhD

Role: backup

+30 6945751020

References

Explore related publications, articles, or registry entries linked to this study.

Zimmet P, M M Alberti KG, Serrano Rios M. [A new international diabetes federation worldwide definition of the metabolic syndrome: the rationale and the results]. Rev Esp Cardiol. 2005 Dec;58(12):1371-6. No abstract available. Spanish.

Reference Type BACKGROUND
PMID: 16371194 (View on PubMed)

Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr; International Diabetes Federation Task Force on Epidemiology and Prevention; Hational Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009 Oct 20;120(16):1640-5. doi: 10.1161/CIRCULATIONAHA.109.192644. Epub 2009 Oct 5.

Reference Type BACKGROUND
PMID: 19805654 (View on PubMed)

Martin-Timon I, Sevillano-Collantes C, Segura-Galindo A, Del Canizo-Gomez FJ. Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength? World J Diabetes. 2014 Aug 15;5(4):444-70. doi: 10.4239/wjd.v5.i4.444.

Reference Type BACKGROUND
PMID: 25126392 (View on PubMed)

Saklayen MG. The Global Epidemic of the Metabolic Syndrome. Curr Hypertens Rep. 2018 Feb 26;20(2):12. doi: 10.1007/s11906-018-0812-z.

Reference Type BACKGROUND
PMID: 29480368 (View on PubMed)

Lesjak V, Stanojevic-Jerkovic O. Physical Activity, Sedentary Behavior and Substance Use among Adolescents in Slovenian Urban Area. Zdr Varst. 2015 Jun 9;54(3):168-74. doi: 10.1515/sjph-2015-0024. eCollection 2015 Sep.

Reference Type BACKGROUND
PMID: 27646724 (View on PubMed)

Scuteri A, Laurent S, Cucca F, Cockcroft J, Cunha PG, Manas LR, Mattace Raso FU, Muiesan ML, Ryliskyte L, Rietzschel E, Strait J, Vlachopoulos C, Volzke H, Lakatta EG, Nilsson PM; Metabolic Syndrome and Arteries Research (MARE) Consortium. Metabolic syndrome across Europe: different clusters of risk factors. Eur J Prev Cardiol. 2015 Apr;22(4):486-91. doi: 10.1177/2047487314525529. Epub 2014 Mar 19.

Reference Type BACKGROUND
PMID: 24647805 (View on PubMed)

Devers MC, Campbell S, Simmons D. Influence of age on the prevalence and components of the metabolic syndrome and the association with cardiovascular disease. BMJ Open Diabetes Res Care. 2016 Apr 25;4(1):e000195. doi: 10.1136/bmjdrc-2016-000195. eCollection 2016.

Reference Type BACKGROUND
PMID: 27158519 (View on PubMed)

Kraja AT, Borecki IB, North K, Tang W, Myers RH, Hopkins PN, Arnett D, Corbett J, Adelman A, Province MA. Longitudinal and age trends of metabolic syndrome and its risk factors: the Family Heart Study. Nutr Metab (Lond). 2006 Dec 5;3:41. doi: 10.1186/1743-7075-3-41.

Reference Type BACKGROUND
PMID: 17147796 (View on PubMed)

Athyros VG, Ganotakis ES, Bathianaki M, Monedas I, Goudevenos IA, Papageorgiou AA, Papathanasiou A, Kakafika AI, Mikhailidis DP, Elisaf M; MetS-Greece Collaborative Group. Awareness, treatment and control of the metabolic syndrome and its components: a multicentre Greek study. Hellenic J Cardiol. 2005 Nov-Dec;46(6):380-6.

Reference Type BACKGROUND
PMID: 16422124 (View on PubMed)

Park MJ, Kim HS. Evaluation of mobile phone and Internet intervention on waist circumference and blood pressure in post-menopausal women with abdominal obesity. Int J Med Inform. 2012 Jun;81(6):388-94. doi: 10.1016/j.ijmedinf.2011.12.011. Epub 2012 Jan 21.

Reference Type BACKGROUND
PMID: 22265810 (View on PubMed)

Konerding U, Elkhuizen SG, Faubel R, Forte P, Malmstrom T, Pavi E, Janssen MF. The validity of the EQ-5D-3L items: an investigation with type 2 diabetes patients from six European countries. Health Qual Life Outcomes. 2014 Dec 5;12:181. doi: 10.1186/s12955-014-0181-5.

Reference Type BACKGROUND
PMID: 25479769 (View on PubMed)

Kokaliari ED, Roy AW. Validation of the Greek translation of the multicultural quality of life index (MQLI-gr). Health Qual Life Outcomes. 2020 Jun 15;18(1):183. doi: 10.1186/s12955-020-01426-9.

Reference Type BACKGROUND
PMID: 32539776 (View on PubMed)

Liu D, Maimaitijiang R, Gu J, Zhong S, Zhou M, Wu Z, Luo A, Lu C, Hao Y. Using the Unified Theory of Acceptance and Use of Technology (UTAUT) to Investigate the Intention to Use Physical Activity Apps: Cross-Sectional Survey. JMIR Mhealth Uhealth. 2019 Aug 22;7(9):e13127. doi: 10.2196/13127.

Reference Type BACKGROUND
PMID: 31507269 (View on PubMed)

Soldatos CR, Dikeos DG, Paparrigopoulos TJ. Athens Insomnia Scale: validation of an instrument based on ICD-10 criteria. J Psychosom Res. 2000 Jun;48(6):555-60. doi: 10.1016/s0022-3999(00)00095-7.

Reference Type BACKGROUND
PMID: 11033374 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

857223

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

488

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.